introduct
respiratori
virus
increasingli
recogn
signific
etiolog
pneumonia
among
hospit
patient
advanc
technolog
use
multiplex
molecular
assay
polymerasechain
reaction
increas
abil
identifi
viral
pathogen
may
ultim
impact
antibacteri
use
method
singlecent
retrospect
cohort
studi
evalu
impact
antibacteri
viral
pneumonia
clinic
outcom
subsequ
multidrugresist
organ
mdro
infectionscolon
patient
admit
march
novemb
posit
respiratori
viral
panel
rvp
radiograph
find
pneumonia
includ
patient
transfer
outsid
hospit
still
hospit
hour
rvp
report
date
exclud
patient
categor
base
exposur
system
antibacteri
less
day
repres
shortcours
therapi
day
longcours
therapi
result
total
patient
longcours
n
shortcours
n
mix
bacterialvir
infect
n
includ
immunocompromis
activ
malign
primari
etiolog
rhinovirusenteroviru
influenza
parainfluenza
virus
commonli
identifi
total
differ
system
antibacteri
use
empir
therapi
patient
pure
viral
infect
total
daysoftherapi
vancomycin
cefepim
azithromycin
meropenem
linezolid
frequent
use
inhospit
mortal
differ
patient
viral
pneumonia
shortcours
longcours
group
subsequ
infectioncolon
mdro
frequent
longcours
group
compar
shortcours
group
vs
p
conclus
studi
found
longcours
antibacteri
use
set
viral
pneumonia
impact
clinic
outcom
increas
incid
subsequ
mdro
infectioncolon
interact
viral
bacteri
respiratori
pathogen
recogn
date
back
influenza
pandem
bacteri
pneumonia
wellrecogn
seriou
complic
influenza
infect
coinfect
commonplac
respiratori
syncyti
viru
rsv
parainfluenza
virus
rhinovirus
adenovirus
also
link
bacteri
coinfect
human
anim
studi
suggest
synerg
bacteri
pathogen
respiratori
virus
relationship
viral
bacteri
respiratori
infect
creat
difficult
situat
clinician
determin
appropri
use
antimicrobi
treat
hospit
patient
pneumonia
also
tri
minim
develop
select
resist
organ
respiratori
virus
increasingli
recogn
primari
etiolog
pneumonia
among
patient
requir
hospit
pneumonia
case
advanc
technolog
use
multiplex
molecular
assay
pcr
improv
diagnost
abil
identifi
viral
pathogen
time
manner
may
impact
use
antibacteri
patient
bacteri
infect
identifi
sever
studi
investig
impact
respiratori
viral
pathogen
identif
antibacteri
exposur
decreas
antibiot
use
observ
two
pediatr
studi
assess
impact
rapid
viral
diagnost
test
respiratori
tract
infect
howev
result
mirror
similar
adult
studi
studi
use
immunofluoresc
stain
primari
diagnost
technolog
knowledg
one
studi
use
pcrbase
respiratori
viru
detect
report
found
chang
antibacteri
use
improv
diagnos
lower
respiratori
tract
infect
broadspectrum
antibacteri
exposur
increas
risk
subsequ
infect
multidrugresist
organ
mdro
lead
viciou
cycl
empir
broadspectrum
antibacteri
combat
increasingli
resist
organ
other
previous
shown
patient
cultureneg
pneumonia
frequent
receiv
treatment
broadspectrum
antibiot
usual
excess
day
therapi
despit
lack
evid
bacteri
etiolog
infect
import
recogn
studi
perform
prior
avail
rapid
viral
diagnost
may
influenc
antibiot
use
studi
period
use
new
diagnost
technolog
respiratori
viru
detect
could
decreas
unnecessari
antibacteri
exposur
subsequ
mdro
infect
studi
aim
describ
use
continu
empir
antibacteri
patient
known
viral
pneumonia
determin
impact
therapi
subsequ
bacteri
infectionscolon
clinic
outcom
singlecent
retrospect
cohort
studi
patient
posit
respiratori
viru
panel
rvp
barnesjewish
hospit
bjh
urban
academ
medic
center
st
loui
mo
usa
march
novemb
studi
protocol
approv
bjh
washington
univers
st
loui
colleg
pharmaci
institut
review
board
consecut
patient
year
age
admit
bjh
hour
assess
studi
inclus
patient
identifi
queri
intern
databas
track
respiratori
virus
patient
admiss
respiratori
viru
identifi
filmarray
respiratori
panel
farp
assay
biofir
diagnost
salt
lake
citi
ut
usa
screen
inclus
studi
includ
patient
meet
studi
definit
viral
pneumonia
patient
admiss
exclud
rhinoviru
enteroviru
identifi
nasopharyng
np
swab
alon
could
also
includ
identifi
lower
respiratori
tract
specimen
addit
patient
exclud
viru
identifi
rvp
within
previou
day
bacteri
pathogen
identifi
respiratori
panel
patient
transfer
outsid
hospit
dischargeddi
made
comfort
care
less
hour
index
rvp
report
date
also
exclud
better
evalu
continu
empir
antibacteri
use
popul
farp
assay
multiplex
nucleic
acid
test
capabl
simultan
qualit
detect
identif
multipl
respiratori
viral
bacteri
nucleic
acid
viral
pneumonia
defin
identif
respiratori
viru
farp
new
progress
radiograph
infiltr
within
hour
index
rvp
shortcours
antibacteri
administr
defin
treatment
system
antibacteri
less
day
longcours
therapi
defin
day
antibiot
index
rvp
report
date
bacteri
infect
identifi
point
admiss
mdro
defin
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
vre
bacterium
exhibit
vitro
resist
least
one
drug
class
antibacteri
organ
intrins
resist
subsequ
isol
mdro
defin
isol
studydefin
mdro
posit
epidemiolog
screen
mrsa
np
swab
vre
stool
specimen
day
report
date
index
rvp
posit
epidemiolog
screen
mrsa
vre
consid
subsequ
colon
mdro
patient
least
one
screen
previou
day
screen
test
neg
prior
index
rvp
immunocompromis
statu
defin
diagnosi
human
immunodefici
viru
hiv
activ
malign
stem
cell
transplant
receiv
chemotherapi
solid
organ
transplant
current
immunosuppress
therapi
prednison
mgday
least
day
equival
inform
regard
farp
includ
time
collectionreport
type
specimen
patient
locat
time
collect
result
find
obtain
intern
databas
addit
avail
aerob
anaerob
bacteri
cultur
evalu
base
electron
medic
record
emr
queri
vitro
suscept
isol
bacteri
pathogen
evalu
report
per
institut
practic
urin
legionella
antigen
directfluoresc
antibodi
pneumocysti
jiroveci
clostridium
difficil
toxin
assay
also
evalu
data
collect
describ
patient
group
includ
demograph
inform
comorbid
condit
clinic
outcom
charlson
comorbid
index
use
summ
score
underli
diseas
state
antibacteri
exposur
calcul
use
emr
order
system
antibacteri
day
therapi
dot
dot
normal
per
patientday
calcul
describ
previous
emr
queri
use
acquir
patient
inform
possibl
manual
chart
review
use
valid
supplement
emr
queri
primari
endpoint
subsequ
isol
mdro
day
index
rvp
report
date
inhospit
mortal
readmiss
day
secondari
endpoint
dichotom
variabl
compar
use
chisquar
test
fisher
exact
test
appropri
continu
variabl
compar
use
mannwhitney
u
test
test
twotail
p
consid
signific
univari
analys
perform
compar
group
receiv
longcours
antibacteri
group
receiv
shortcours
antibacteri
therapi
kaplanmei
surviv
analysi
use
compar
risk
inhospit
mortal
compar
group
censor
patient
discharg
statist
analys
perform
use
spss
softwar
ibm
spss
statist
version
chicago
il
usa
total
consecut
patient
long
cours
n
short
cours
n
mix
bacterialvir
infect
n
includ
studi
fig
demograph
clinic
characterist
summar
tabl
median
age
year
male
major
patient
cohort
deem
immunocompromis
activ
malign
common
etiolog
patient
admit
within
day
prior
index
admiss
figur
provid
breakdown
subgroup
patient
screen
emerg
depart
set
accord
presenc
pure
viral
mix
infect
rhinovirusenteroviru
influenza
parainfluenza
virus
commonli
identifi
cohort
tabl
total
patient
multipl
respiratori
virus
identifi
rvp
rsv
rhinovirusenteroviru
influenza
human
metapneumoviru
parainfluenza
coronaviru
adenoviru
specimen
result
posit
respiratori
viru
cohort
includ
np
swab
bronchoalveolar
lavag
tracheal
aspir
bronchial
wash
sputum
sampl
rvp
identifi
respiratori
viru
multipl
specimen
patient
among
patient
multipl
posit
specimen
common
bronchoalveolar
lavag
patient
tracheal
aspir
patient
signific
differ
comorbid
group
identifi
tabl
patient
mix
viralbacteri
infect
statist
greater
apach
ii
score
like
requir
vasopressor
support
compar
patient
pure
viral
infect
signific
differ
number
immunocompromis
patient
group
although
numer
patient
receiv
longcours
antibacteri
activ
malign
solid
organ
transplant
compar
patient
receiv
shortcours
therapi
viru
type
identifi
farp
assay
similar
three
patient
group
tabl
bacteri
coinfect
organ
identifi
patient
mix
viralbacteri
infect
present
tabl
respiratori
coinfect
bacteri
pathogen
common
aureu
streptococcu
pneumonia
pseudomona
aeruginosa
account
frequent
respiratori
coinfect
bacteria
total
differ
system
antibacteri
use
empir
treatment
patient
viral
pneumonia
without
bacteri
coinfect
total
dot
vancomycin
cefepim
azithromycin
meropenem
linezolid
frequent
use
empir
antibacteri
patient
viral
pneumonia
without
bacteri
coinfect
fig
common
regimen
use
viral
pneumonia
without
bacteri
coinfect
vancomycin
plu
cefepim
vancomycin
plu
meropenem
total
patient
viral
pneumonia
without
bacteri
coinfect
receiv
empir
mrsa
coverag
vancomycin
linezolid
empir
antibacteri
therapi
continu
median
day
interquartil
rang
day
viral
pneumonia
without
bacteri
coinfect
day
intraven
antibacteri
total
antibacteri
exposur
differ
longcours
shortcours
group
dot
respect
number
patient
subsequ
mdro
colon
infect
significantli
differ
group
tabl
howev
instanc
subsequ
infect
colon
singl
patient
could
one
organ
higher
rate
mdro
identif
among
isol
group
receiv
longcours
antibacteri
compar
group
receiv
shortcours
therapi
vs
p
tabl
inhospit
mortal
statist
higher
mixedinfect
group
compar
longcours
therapi
group
tabl
kaplanmei
surviv
analysi
show
mixedinfect
group
lowest
overal
surviv
differ
statist
icu
admit
determin
oncolog
relat
patient
fit
studi
definit
activ
malign
statist
signific
differ
p
longcours
mixedinfect
group
statist
signific
differ
p
shortcours
mixedinfect
group
bmi
bodi
mass
index
cci
charlson
comorbid
index
copd
chronic
obstruct
pulmonari
diseas
esrd
endstag
renal
diseas
signific
fig
icu
mortal
also
significantli
higher
patient
mixedinfect
group
compar
longcours
therapi
group
patient
receiv
longcours
therapi
mix
infect
statist
longer
icu
length
stay
compar
patient
receiv
shortcours
therapi
hospit
readmiss
rate
similar
group
day
index
hospit
discharg
studi
compar
cohort
patient
viral
pneumonia
mix
viralbacteri
infect
base
exposur
continu
empir
antibacteri
respiratori
viru
identif
subsequ
infect
colon
bacteri
isol
group
pure
viral
pneumonia
receiv
continu
longcours
antibacteri
defin
mdro
compar
shortcours
group
p
find
suggest
prolong
exposur
broadspectrum
antibacteri
patient
viral
pneumonia
may
promot
resist
patient
benefit
continu
empir
antibacteri
patient
pure
viral
pneumonia
seen
studi
risk
bacteri
coinfect
set
viral
pneumonia
especi
influenza
creat
challeng
situat
clinician
potenti
detriment
impact
treat
bacteri
pathogen
weigh
data
express
number
total
median
interquartil
rang
lo
length
stay
mdro
multidrugresist
organ
mrsa
methicillinresist
staphylococcu
aureu
vre
vancomycinresist
enterococci
statist
signific
differ
p
shortcours
longcours
group
statist
signific
differ
p
longcours
mixedinfect
group
statist
signific
differ
p
shortcours
mixedinfect
group
heavili
decis
process
downstream
effect
therapi
may
disregard
find
similar
clinic
outcom
patient
pure
viral
pneumonia
receiv
longcours
antibacteri
viru
recognit
may
suggest
opportun
deescal
empir
antibacteri
therapi
viral
pneumonia
identifi
previou
random
control
trial
oosterheert
et
al
evalu
implement
realtim
pcr
rapid
diagnost
respiratori
pathogen
identif
found
increas
diagnost
yield
assay
differ
antibiot
use
hypothes
reluct
chang
treatment
base
test
result
may
inhibit
costeffect
demonstr
studi
system
antibacteri
discontinu
follow
identif
respiratori
viru
rvp
sever
patient
howev
whether
viru
identif
directli
led
discontinu
antibacteri
determin
willing
prescrib
deescal
stop
antibacteri
set
may
suggest
increas
recognit
role
viral
pathogen
pneumonia
addit
expand
panel
virus
detect
may
factor
result
perceiv
prescrib
may
like
attribut
pneumonia
newli
detect
virus
human
metapneumoviru
howev
possibl
definit
determin
rational
stop
antibacteri
therapi
time
antibiot
administr
crucial
treat
hospit
patient
suspect
pneumonia
antimicrobi
deescal
attempt
balanc
use
essenti
drug
front
emerg
resist
optim
strategi
deescal
antibacteri
set
viral
pneumonia
without
identifi
bacteri
coinfect
unclear
studi
found
differ
clinic
outcom
base
antibiot
durat
therapi
patient
viral
pneumonia
despit
significantli
differ
total
antibacteri
exposur
group
byington
et
al
found
previous
improv
diagnost
technolog
enhanc
detect
respiratori
virus
decreas
antibacteri
use
children
hospit
author
conclud
improv
diagnost
import
tool
decreas
unnecessari
antibacteri
prescrib
studi
similarli
illustr
potenti
impact
respiratori
viru
diagnost
antibacteri
use
adult
popul
c
difficil
infect
major
caus
morbid
mortal
us
hospit
directli
link
exposur
broadspectrum
antibiot
cohort
hospit
adult
patient
shiley
et
al
found
significantli
patient
continu
receiv
antibacteri
diagnosi
viral
respiratori
tract
infect
develop
c
difficil
infect
one
patient
studi
treat
longcours
antibacteri
identif
respiratori
viru
also
develop
c
difficil
infect
strategi
best
limit
use
unneed
antibacteri
import
curtail
grow
issu
c
difficil
resist
may
aid
deescal
approach
use
enhanc
viral
diagnost
technolog
limit
studi
note
first
small
retrospect
cohort
studi
patient
singl
institut
may
repres
set
import
note
bjh
region
specialti
referr
hospit
commun
hospit
account
case
mix
high
preval
immunosuppress
patient
low
preval
narrow
spectrum
empir
antibiot
util
small
number
patient
meet
inclus
criteria
allow
definit
conclus
made
regard
group
comparison
lack
statist
signific
differ
found
could
due
lack
sampl
size
second
patient
determin
viral
pneumonia
base
viru
identif
radiograph
find
marker
ill
white
blood
cell
count
fever
consid
retrospect
natur
studi
allow
evalu
drove
continu
antibacteri
patient
other
moreov
attempt
identifi
risk
factor
associ
pure
viral
pneumonia
third
although
coinfect
bacteri
pathogen
identifi
patient
pure
viral
pneumonia
imposs
prove
present
receipt
antibacteri
prior
obtain
bacteri
cultur
could
limit
diagnost
yield
bacteri
cultur
case
yield
bacteri
cultur
perfect
final
viral
pneumonia
case
occur
period
viral
epidemiolog
time
may
repres
season
influenza
primari
influenza
viru
identifi
studi
incid
rate
bacteri
coinfect
coinfect
organ
may
differ
year
year
viru
type
viru
type
may
hinder
applic
deescal
strategi
use
result
studi
possibl
directli
link
develop
subsequ
mdro
infectionscolon
c
difficil
infect
seen
studi
continu
empir
antibacteri
administ
patient
includ
cohort
receiv
antibacteri
point
index
hospit
infect
control
measur
directli
assess
patient
addit
hospit
probabl
increas
risk
patient
colon
mdro
use
cephalosporin
vancomycin
two
commonli
administ
empir
agent
studi
implic
increas
preval
vre
commonli
identifi
subsequ
mdro
studi
decreas
exposur
broadspectrum
antibacteri
thirdgener
fourthgener
cephalosporin
vancomycin
would
expect
lessen
incid
vre
mdro
seen
studi
risk
develop
transmiss
resist
hospit
complet
elimin
antibacteri
extraordinarili
import
treatment
mani
hospit
patient
use
often
warrant
decreas
unnecessari
use
may
help
curb
acquir
resist
organ
healthcar
set
even
appropri
use
lead
develop
resist
multifacet
effort
infect
control
antimicrobi
stewardship
spread
mdro
patient
clinician
worker
visitor
diminish
studi
highlight
potenti
benefit
improv
diagnost
respiratori
virus
primarili
potenti
decreas
antibacteri
exposur
thu
decreas
select
pressur
resist
bacteri
isol
antibacteri
exposur
appli
select
pressur
promot
colonizationinfect
resist
organ
includ
mrsa
vre
halt
process
essenti
maintain
effect
therapeut
option
futur
may
aid
discontinu
antibacteri
case
viral
pneumonia
studi
patient
viral
pneumonia
expos
longcours
antibacteri
occurr
subsequ
infect
colon
mdro
isol
contrast
number
patient
subsequ
mdro
infect
colon
differ
group
although
may
due
small
number
patient
group
differ
clinic
outcom
includ
inhospit
mortal
readmiss
rate
observ
patient
group
set
viral
pneumonia
coinfect
bacteri
pathogen
discontinu
antibacteri
reason
mani
case
may
allow
decreas
overal
antibacteri
use
enhanc
diagnost
technolog
potenti
incorpor
antimicrobi
stewardship
practic
allow
deescal
unnecessari
antibacteri
find
warrant
investig
determin
applic
antibacteri
deescal
approach
set
viral
pneumonia
singlecent
retrospect
cohort
patient
viral
pneumonia
continu
treat
system
antibacteri
day
viru
identif
like
subsequ
infect
colon
mdro
patient
system
antibacteri
stop
inhospit
mortal
base
kaplanmei
surviv
analysi
readmiss
rate
differ
group
base
antibacteri
exposur
respiratori
viru
identif
author
declar
compet
interest
